

1 October 2025

### Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

### Block Listing Return

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of <i>applicant</i> :		Cambridge Cognition Holdings plc		
Name of scheme:		Share Options		
Period of return:	From:	1 April 2025	To:	30 September 2025
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:		1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023		
Balance of unallotted securities under scheme(s) from previous return:		466,316 ordinary shares		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
Less: Number of <i>securities</i> issued/allotted under scheme(s) during period:		Nil		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		466,316 ordinary shares		

Name of contact:	Simon McKeating
Telephone number of contact:	+44 (0)1223 810700

### Enquiries:

<b>Cambridge Cognition Holdings plc</b>		Tel: 012 2381 0700
Rob Baker, Senior Executive Director and Group Chief Operating Officer		<a href="mailto:press@camcog.com">press@camcog.com</a>
<b>Panmure Liberum Limited (NOMAD and Joint Broker)</b>		Tel: 020 7886 2968
Will Goode / Mark Rogers / Freddy Crossley		(Corporate Finance)
Rupert Dearden		(Corporate Broking)
<b>Dowgate Capital Limited (Joint Broker)</b>		Tel: 020 3903 7715
David Poutney / Amber Higgs		

### Notes to Editors

#### About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

- **Clinical Studies** for new pharmaceuticals;
- **Academic Research** for scientists to understand CNS disorders;
- **Healthcare** to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
- **Consumer Health & Wellness** to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health

assess their cognitive health.

For further information, visit: [www.cambridgecognition.com](http://www.cambridgecognition.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLREALNEDEDESEFA